MBX Biosciences Eyes $482.5M Valuation for US IPO
On Monday, MBX Biosciences, which is developing peptide therapies for treating endocrine and metabolic disorders, including obesity, said it was […]
MBX Biosciences Eyes $482.5M Valuation for US IPO Read More »